论文部分内容阅读
目的观察垂体后叶素联合酚妥拉明治疗支气管扩张大咯血的临床疗效。方法从2009年9月～2011年11月我院收治的支气管扩张大咯血的案例中选取60例,按随机原则予以垂体后叶素治疗30例,为对照组;30例予以垂体后叶素联合酚妥拉明治疗,标为观察组。观察两组咯血的变化情况、止血时间及不良反应。结果总有效率:观察组96.67%,高于对照组76.67%;止血时间:观察组(3.4±0.9)d,少于对照组(6.1±1.2)d;不良反应:观察组3例(10%),少于对照组8例(26.67%),且差异具有统计学意义(P<0.05)。结论在基础治疗前提下,垂体后叶素联合酚妥拉明治疗支气管扩张大咯血治效果明显,值得临床推广。
Objective To observe the clinical efficacy of pituitrin and phentolamine in the treatment of bronchiectasis and hemoptysis. Methods From September 2009 to November 2011, 60 cases of bronchiectasis and massive hemoptysis were treated in our hospital. Thirty patients with pituitrin were randomly divided into control group and 30 patients with pituitrin combined Phentolamine treatment, marked as observation group. Observe the changes of hemoptysis, hemostasis time and adverse reactions in both groups. Results The total effective rate was 96.67% in the observation group and 76.67% in the control group. The bleeding time was 3.4 ± 0.9 days in the observation group and 6.1 ± 1.2 days in the control group. Adverse reactions were observed in 3 cases (10% ), Less than the control group, 8 cases (26.67%), and the difference was statistically significant (P <0.05). Conclusion Under the premise of basic treatment, pituitrin combined with phentolamine treatment of bronchiectasis is significant, worthy of clinical promotion.